| Dr Michael H Golf, DPM | |
|
4310 James Casey St, Suite 3a, Austin, TX 78745-1251 | |
| (512) 448-3668 | |
| (512) 448-4460 |
| Full Name | Dr Michael H Golf |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 47 Years |
| Location | 4310 James Casey St, Austin, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588673420 | NPI | - | NPPES |
| 121562602 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0131X | Podiatrist - Foot Surgery | 0582 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Austin Podiatry Pa | 8527245208 | 3 |
News Archive
News outlets also report on whether health exchanges will end insurance monopolies; on efforts to address possible "churning" between Medicaid and the new insurance marketplaces; and the money states spent to decide against running their own exchanges.
Congress is approving still more money to address the health and economic fallout of the ongoing novel coronavirus pandemic.
Significant weaknesses undermine the global community's abilities to prevent, detect early, and respond efficiently to potentially deadly species-crossing microbes, such as the pandemic H1N1 influenza virus sweeping the globe, says a new report from the Institute of Medicine and National Research Council. The report provides a detailed plan for establishing and funding a comprehensive, globally coordinated system to identify novel zoonotic disease threats as early as possible wherever they arise so appropriate measures can be taken to prevent significant numbers of human illnesses and deaths, and livestock losses.
Dainippon Sumitomo Pharma Co., Ltd. ("DSP", TSE: 4506) and Sepracor Inc. ("Sepracor", Nasdaq: SEPR) today announced that they have entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share, followed by a merger to acquire all remaining outstanding Sepracor shares at the same price paid in the tender offer.
e-Therapeutics plc announces that it has started a second phase I clinical trial of its anti-cancer drug ETS2101. This trial will enrol up to 45 patients with a variety of solid tumours at two UK centres, St James's University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle.
› Verified 5 days ago
| Provider Name | Austin Podiatry Pa |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1669625901 PECOS PAC ID: 8527245208 Enrollment ID: O20110606000599 |
News Archive
News outlets also report on whether health exchanges will end insurance monopolies; on efforts to address possible "churning" between Medicaid and the new insurance marketplaces; and the money states spent to decide against running their own exchanges.
Congress is approving still more money to address the health and economic fallout of the ongoing novel coronavirus pandemic.
Significant weaknesses undermine the global community's abilities to prevent, detect early, and respond efficiently to potentially deadly species-crossing microbes, such as the pandemic H1N1 influenza virus sweeping the globe, says a new report from the Institute of Medicine and National Research Council. The report provides a detailed plan for establishing and funding a comprehensive, globally coordinated system to identify novel zoonotic disease threats as early as possible wherever they arise so appropriate measures can be taken to prevent significant numbers of human illnesses and deaths, and livestock losses.
Dainippon Sumitomo Pharma Co., Ltd. ("DSP", TSE: 4506) and Sepracor Inc. ("Sepracor", Nasdaq: SEPR) today announced that they have entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share, followed by a merger to acquire all remaining outstanding Sepracor shares at the same price paid in the tender offer.
e-Therapeutics plc announces that it has started a second phase I clinical trial of its anti-cancer drug ETS2101. This trial will enrol up to 45 patients with a variety of solid tumours at two UK centres, St James's University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael H Golf, DPM 4310 James Casey St Ste 3a, Austin, TX 78745-1120 Ph: (512) 448-3668 | Dr Michael H Golf, DPM 4310 James Casey St, Suite 3a, Austin, TX 78745-1251 Ph: (512) 448-3668 |
News Archive
News outlets also report on whether health exchanges will end insurance monopolies; on efforts to address possible "churning" between Medicaid and the new insurance marketplaces; and the money states spent to decide against running their own exchanges.
Congress is approving still more money to address the health and economic fallout of the ongoing novel coronavirus pandemic.
Significant weaknesses undermine the global community's abilities to prevent, detect early, and respond efficiently to potentially deadly species-crossing microbes, such as the pandemic H1N1 influenza virus sweeping the globe, says a new report from the Institute of Medicine and National Research Council. The report provides a detailed plan for establishing and funding a comprehensive, globally coordinated system to identify novel zoonotic disease threats as early as possible wherever they arise so appropriate measures can be taken to prevent significant numbers of human illnesses and deaths, and livestock losses.
Dainippon Sumitomo Pharma Co., Ltd. ("DSP", TSE: 4506) and Sepracor Inc. ("Sepracor", Nasdaq: SEPR) today announced that they have entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share, followed by a merger to acquire all remaining outstanding Sepracor shares at the same price paid in the tender offer.
e-Therapeutics plc announces that it has started a second phase I clinical trial of its anti-cancer drug ETS2101. This trial will enrol up to 45 patients with a variety of solid tumours at two UK centres, St James's University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle.
› Verified 5 days ago
Capital Foot & Ankle Surgeons Of Austin, Pllc Podiatrist Medicare: Medicare Enrolled Practice Location: 900 E 30th St, 311, Austin, TX 78705 Phone: 512-474-6666 Fax: 512-474-6668 | |
Mr. Joseph Harold Snowden, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 911 W 38th St Ste 300, Austin, TX 78705 Phone: 512-439-1000 | |
Vikas A Godhania, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 6811 Austin Center Blvd # 300, Austin, TX 78731 Phone: 512-346-8888 Fax: 512-344-0365 | |
J Michael Valenza, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 5656 Bee Cave Rd, Ste D204, Austin, TX 78746 Phone: 512-327-9251 Fax: 512-327-9742 | |
Angela L Drury Pc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 2312 Western Trails, Suite 103, Austin, TX 78745 Phone: 512-382-0773 Fax: 512-382-0072 | |
Dr. Anne Compeau Ames, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1301 W 38th St, Suite 707, Austin, TX 78705 Phone: 512-407-8188 Fax: 512-459-1190 | |
Angela L Drury, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 2312 Western Trails Blvd, Suite 103, Austin, TX 78745 Phone: 512-382-0773 Fax: 512-382-0772 |